Epigenetic inactivation via hypermethylation of promoter CpG island of TFPI2 is associated with TFPI2silencing in pancreatic ductal adenocarcinoma (Sato et al. 2005), gastric cancer (Takada et al. 2010), non-small-cell lung cancer (Rollin et al. 2005) and glioblastomas (Vaitkiene et al. 2012), and contributes to the aggressive phenotype of various tumors. This evidence concerns the gene TFPI2 and non-small cell lung carcinoma.